Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness of Xofigo® (Radium-223 Dichloride) in Routine Clinical Practice Settings in Taiwan

NCT04232761 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04232761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04232761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness of Xofigo® (Radium-223 Dichloride) in Routine Clinical Practice Settings in Taiwan
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
July 7, 2020
Completion date
April 29, 2024
Enrollment
194 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer